FindTrial
Sign In

Infections in patients receiving bendamustine rituximab (BR) chemotherapy

Incidence, clinical profile and outcome of infections in patients receiving bendamustine rituximab (BR) chemotherapy for non-Hodgkins lymphoma: A prospective observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075603
Enrollment
76
Registered
2024-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C859- Non-Hodgkin lymphoma, unspecified

Interventions

Intervention1: NOT APPLICABLE: NOT APPLICABLE Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Sponsors

Dr Anjely Pulparampil Sebastian
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adult patients receiving bendamustine rituximab chemotherapy from date of IEC approval to December 2025.

Exclusion criteria

Exclusion criteria: • Patients with palliative line of treatment • Patients who do not agree to participate

Design outcomes

Primary

MeasureTime frame
Incidence of infectionTimepoint: Every month from recruitment till 6 months—

Secondary

MeasureTime frame
Comparison of clinical profile and outcomes between patients who develop infections and those who do not develop infections after receiving bendamustine-rituximab chemotherapyTimepoint: 0 to 6 months—

Countries

India

Contacts

Public ContactAnjely Pulparampil Sebastian

Kasturba Medical College, Manipal

muralidhar.varma@manipal.edu9845069639

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026